Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HRH1 | P35367 | 19/20 | 1.00 |
| ▸ | CYP2D6 | P10635 | 12/20 | 1.00 |
| ▸ | KCNH2 | Q12809 | 12/20 | 1.00 |
| ▸ | CHRM1 | P11229 | 6/20 | 1.00 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.69 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4843922 | 1.00 | HRH1 (1.00) | HRH1CYP2D6KCNH2CHRM1CYP3A4 | |
| SCHEMBL4845967 | 1.00 | HRH1 (1.00) | HRH1CYP2D6KCNH2CHRM1CYP3A4 | |
| SCHEMBL30208622 | 0.91 | HRH1 (0.83) | HRH1CYP2D6KCNH2CHRM1CYP3A4 | |
| SCHEMBL4843815 | 0.89 | HRH1 (0.79) | HRH1CYP2D6KCNH2CHRM1CYP3A4 | |
| SCHEMBL4846590 | 0.88 | HRH1 (0.78) | HRH1CYP2D6KCNH2CHRM1CYP3A4 | |
| SCHEMBL4846478 | 0.88 | HRH1 (0.78) | HRH1CYP2D6KCNH2CHRM1CYP3A4 | |
| SCHEMBL4843783 | 0.88 | HRH1 (0.78) | HRH1CYP2D6KCNH2CHRM1CYP3A4 | |
| SCHEMBL4851063 | 0.87 | HRH1 (0.77) | HRH1CYP2D6KCNH2CHRM1CYP3A4 | |
| SCHEMBL4843939 | 0.87 | HRH1 (0.77) | HRH1CYP2D6KCNH2CHRM1CYP3A4 | |
| SCHEMBL4849150 | 0.87 | HRH1 (0.77) | HRH1CYP2D6KCNH2CHRM1CYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7393865-B2 | Sleep inducing compounds and methods relating thereto | NEUROCRINE BIOSCIENCES, INC. (US) | 2008-07-01 | — | — | US | claimed |
| WO-2006019497-A2 | SLEEP-INDUCING COMPOUNDS AND METHODS RELATED THERETO | NEUROCRINE BIOSCIENCES, INC. (US) | 2006-02-23 | — | — | WO | claimed |
| US-20060014797-A1 | Sleep inducing compounds and methods relating thereto | NEUROCRINE BIOSCIENCES, INC. (US) | 2006-01-19 | — | — | US | claimed |
| US-7393865-B2 | Sleep inducing compounds and methods relating thereto | NEUROCRINE BIOSCIENCES, INC. (US) | 2008-07-01 | — | — | US | disclosed |
| US-7393865-B2 | Sleep inducing compounds and methods relating thereto | NEUROCRINE BIOSCIENCES, INC. (US) | 2008-07-01 | — | — | US | disclosed |
| US-20060014797-A1 | Sleep inducing compounds and methods relating thereto | NEUROCRINE BIOSCIENCES, INC. (US) | 2006-01-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060014797-A1 | Sleep inducing compounds and methods relating thereto | CHRM1, CNR1, HRH3 | HRH1 11/4885CYP2D6 83/4885KCNH2 1979/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.